Demand is rapidly increasing in Nigeria for a new HIV prevention injection, even before its full nationwide rollout.
Health workers report growing interest in Lenacapavir, a twice-yearly injectable developed by Gilead Sciences and endorsed by the World Health Organization in 2025. The drug provides an alternative to daily HIV prevention pills.
The Nigerian government has already begun pilot distribution in selected states, including Lagos, Kano, Benue and Abuja, with over 11,000 doses delivered so far out of a planned 52,000.
The injection will be offered free of charge at designated public health facilities, though not through private pharmacies.
Despite the enthusiasm, health experts warn of widespread misconceptions. Some people mistakenly believe the drug can cure HIV, when it is designed only to prevent infection in individuals who are HIV-negative.
With around two million people living with HIV in Nigeria, officials see the rollout as a major step in reducing new infections. However, medical professionals stress the importance of proper awareness, safety checks and regulated distribution.
While the drug is currently approved only for non-pregnant individuals, public health advocates say expanding access and education could significantly strengthen HIV prevention efforts across the country.
